Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

clinical trial

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT01886872

P6099clinical trial phasephase III clinical trialQ42824827
P17countryCanadaQ16
P582end time2018-08-07
P1050medical conditionleukemiaQ29496
P2899minimum age65
P1132number of participants545
P4844research interventionrituximabQ412323
bendamustine hydrochlorideQ27272066
immunological antineoplastic agentQ50429626
P6153research siteBoston UniversityQ49110
Yale UniversityQ49112
West Virginia UniversityQ115376
University of ChicagoQ131252
University of PittsburghQ235034
Oregon Health & Science UniversityQ282097
Ohio State UniversityQ309331
University of RochesterQ149990
University of TorontoQ180865
University of North Carolina at Chapel HillQ192334
Stony Brook UniversityQ969850
Case Western Reserve UniversityQ1047060
Wake Forest UniversityQ392667
Southern Illinois University EdwardsvilleQ519349
McMaster UniversityQ632891
Northwestern UniversityQ309350
Georgetown UniversityQ333886
Cedars-Sinai Medical CenterQ1052562
Mayo ClinicQ1130172
Dana–Farber Cancer InstituteQ1159198
University of MiamiQ738258
Creighton UniversityQ770544
York UniversityQ849751
East Carolina UniversityQ1277776
University of ToledoQ2302319
University of Texas Southwestern Medical CenterQ2725999
Brigham and Women's HospitalQ2900977
Newark Beth Israel Medical CenterQ7016630
North Shore Medical CenterQ7056695
Rhode Island HospitalQ7320925
Roswell Park Comprehensive Cancer CenterQ7370121
Saint Luke's HospitalQ7401747
Swedish Medical CenterQ7654755
University Health Truman Medical CenterQ7847720
Tufts University School of Arts and SciencesQ7851547
University of Mississippi Medical CenterQ7895818
University of Nebraska Medical CenterQ7895888
University of Oklahoma Health Sciences CenterQ7896014
Washington Hospital CenterQ7971940
University of Illinois Urbana–ChampaignQ457281
University of AlabamaQ492318
Rutgers UniversityQ499451
Elkhart General HospitalQ87932226
Washington University School of MedicineQ7972509
Newton-Wellesley HospitalQ14715774
Hurley Medical CenterQ14716149
Decatur Memorial HospitalQ22033932
MetroHealth Medical CenterQ30254005
Delaware County Memorial HospitalQ30254340
UNM Los LunasQ30258334
21st Century Oncology (United States)Q30269404
Sky Ridge Medical CenterQ30270451
Duke University Medical CenterQ30279912
Jewish HospitalQ30280293
Rapid City Regional HospitalQ30280592
Aurora Sinai Medical CenterQ30280597
Wentworth Douglass HospitalQ30281118
Mercy Medical CenterQ30281132
Comprehensive Cancer Centers of NevadaQ30286943
Jupiter Medical CenterQ30288257
West Michigan Cancer CenterQ30289179
Colorado Blood Cancer InstituteQ43896855
Aurora BayCare Medical CenterQ50036553
Freeman Health SystemQ50039515
Penobscot Bay Medical Center heliportQ61673301
Denver Health Medical CenterQ3023367
AdventHealth PorterQ3145247
Jewish General HospitalQ3145341
Norwalk HospitalQ3344269
Cleveland ClinicQ4117596
Baystate Medical CenterQ4874851
Bryn Mawr HospitalQ4980899
Danbury HospitalQ5214961
Eastern Maine Medical CenterQ5330270
Englewood Hospital and Medical CenterQ5378128
Fox Chase Cancer CenterQ5476635
Grady Memorial HospitalQ5592136
Greater Baltimore Medical CenterQ5600442
Hennepin County Medical CenterQ5714832
Loyola University Medical CenterQ6694611
Maimonides Medical CenterQ6735870
Medical College of WisconsinQ6806307
Medical University of South CarolinaQ6806451
Memorial Hospital of Rhode IslandQ6815467
Memorial Medical CenterQ6815474
Mission Health SystemQ6878595
Munson Medical CenterQ6936903
P580start time2013-12-09
P8363study typeinterventional studyQ78089383
P1476titleA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)